Skirt­ing a group of pi­o­neers, Gilead part­ners with gene-edit­ing up­start Pre­ci­sion Bio in hunt to cure hep B

Hav­ing al­ready found a pain­less cure for he­pati­tis C, Gilead has now set its sights on an­oth­er cure for he­pati­tis B. And they’ve steered around the most promi­nent gene-edit­ing play­ers in the field to part­ner up Durham, NC-based Pre­ci­sion Bio­Sciences just a cou­ple of months af­ter the biotech raised an im­pres­sive $110 mil­lion mega-crossover round.

Gilead said this morn­ing it has seed­ed their col­lab­o­ra­tion with Pre­ci­sion with $445 mil­lion in mile­stones, avoid­ing any men­tion of an up­front in the an­nounce­ment. 

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.